Detecting tumour cells individually

By Peter Rüegg
Detecting tumour cells individually
A tumour consists of more different genetic variants of cancer cells (in the picture, a lung-cancer cell) than originally believed. Credit: Wellcome Images / Flickr

(Medical Xpress) -- Swiss researchers have devised a method to detect mutations in tumor cells that are only present in a proportion of the cancer’s cells. The analysis reveals that cells of individual tumours are more variable than first thought – and differ from patient to patient.

Sometimes, a tumor only develops very slowly. It begins with a few cells that mutate. Then these cells mutate. And mutate again. The mutants are more successful than their predecessors, outcompeting them as they multiply. Consequently, new variants of cells keep emerging, each fitter than their predecessors: the tumor goes through an evolution that gives rise to a genetically heterogeneous .

This makes it difficult to treat a tumour with medication as there might be cells that do not respond to the drug used. Researchers from ETH Zurich and the Swiss Institute of Bioinformatics thus teamed up with colleagues from the University of Zurich to develop a new method for determining the genetic variants of reliably. Using this method, the researchers are able to detect mutations that only appear in one in every 10,000 cells.

Test on renal cancer tissue successful

“This method will be important for use in clinics, for instance, when therapy-resistant cell types need to be detected to adapt the treatment accordingly,” says lead author Moritz Gerstung from ETH Zurich’s Department of Biosystems Science and Engineering. The study has just been published in Nature Communications.

The new approach also enables to measure the frequency of certain variants within the tumour-cell population, which sheds light on how tumours grow and how quickly they change genetically inside the patient.

In a comparison of two particular regions of two genes from healthy renal cells and cells, the researchers found twenty-four gene variants. Some variants were only present in two in every 10,000 cells examined; others, however, in over a third.

Statistics compensate for read errors

For their method, the researchers genetically analyzed countless tumor cells from renal cancer tissue using a modern sequencing technique called “deep sequencing”. As a result, millions of DNA fragments from single genes were sequenced simultaneously. These DNA fragments are isolated from the entire population of tumor cells and shed light on the genetic composition of the tumor. These genes were sequenced over 100,000 times, which corresponds to equally as many individually sequenced cells.

In reading the genetic code, however, errors can occur. So as not to mistake these errors for actual mutations, the researchers sequenced healthy tissue in parallel to be able to determine the error rate at any point on the DNA. In order to distinguish actual mutations from sequencing errors at a particular point, they developed a special statistical algorithm. “This was a critical step for us as even the tiniest of inaccuracies can cause a large number of errors because the algorithm analyses several million DNA fragments,” says Dr. Gerstung.

Personalized cancer medicine the aim

The researchers began by testing their new method on control samples with a known cell composition to make sure that it worked and did not display any false forecasts. Then they analysed four tumor samples and found numerous or subtypes . “Their existence supports the theory that tumours change constantly in accordance with a Darwinian evolutionary process,” says Dr. Gerstung.

The new method helps personalise cancer therapy further. In future, tumors may not be treated as a unit. If one knows which cell types a tumor contains, the therapy can be adapted individually to a specific combination of drugs. When and whether the method will be used routinely in clinics remains to be seen. Further research is required to determine how tumor cell populations respond to different treatments. “However, the method is already at a stage where it can be also used for other cancer types,” says the ETH-Zurich researcher.

More information: Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H & Beerenwinkel N. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nature Communications, published online on 2 May 2012. doi: 10.1038/ncomms1814

Related Stories

Cancer cells more likely to genetically mutate

date Feb 19, 2007

When cells become cancerous, they also become 100 times more likely to genetically mutate than regular cells, researchers have found. The findings may explain why cells in a tumor have so many genetic mutations, but could ...

An ABSOLUTEly new view of the cancer genome

date May 04, 2012

(Medical Xpress) -- Scientists hoping to unlock cancer’s secrets face a formidable challenge. Sophisticated research tools have allowed them to peer into the genomes of cancer cells and identify many ...

Recommended for you

To stop cancer: Block its messages

date 1 hour ago

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions ...

Researchers develop new potential drug for rare leukemia

date 2 hours ago

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest ...

How immune cells facilitate the spread of breast cancer

date 2 hours ago

The body's immune system fights disease, infections and even cancer, acting like foot soldiers to protect against invaders and dissenters. But it turns out the immune system has traitors amongst their ranks. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.